Half-Life vs Duration of Action: Why 'Cleared From Blood' Isn't 'No Longer Working'

A drug can be almost gone from your blood and still be working, and it can be sitting at high blood levels and barely doing anything. That is the gap between half-life and duration of action, and confusing the two is one of the most common mistakes in reading a compound’s profile. Half-life tells you how fast the drug leaves circulation; the Peptide Half-Life Visualizer plots that. Duration of action is a separate question the clearance curve cannot answer on its own. This article explains what decouples them, in both directions.

Two different questions

The distinction is pharmacokinetics versus pharmacodynamics:

• Half-life (pharmacokinetics) answers “how fast does the drug leave the blood?” It is about concentration over time, the halving curve covered in what a peptide’s half-life actually is.
• Duration of action (pharmacodynamics) answers “how long does the effect last?” It is about what the drug does after it binds: receptor occupancy, downstream signaling, and how long those persist.

Half-life is a pharmacokinetic number (how fast blood levels fall); duration of action is a pharmacodynamic one (how long the effect lasts). They are related but not the same.

If drug concentration and drug effect moved in perfect lockstep, half-life would tell you duration and this article would not need to exist. In practice they often come apart, and the direction of the mismatch matters.

When effects outlast blood levels

This is the more striking case: the drug is mostly cleared, yet the effect continues. Several mechanisms drive it.

• Tight or slow-releasing receptor binding. If a molecule clings to its receptor, the effect tracks receptor occupancy, not plasma concentration. The classic documented example is dihydroergotamine, which relieves migraine for up to 48 hours despite a serum half-life of only about 10–13 hours. The persistence comes from prolonged binding to serotonin receptors, not from lingering drug in the blood.
• Downstream signaling that keeps running. A peptide may bind briefly, trigger a signaling cascade or gene-expression change, and then leave, while the cascade it started plays out for much longer. The trigger is transient; the consequence is not.
• Active metabolites. Some drugs are broken into fragments that are themselves active, extending the effect beyond the parent compound’s own half-life.

The growth-hormone-releasing peptides show this. In human data, CJC-1295 produced elevated IGF-1 for days to weeks after dosing. The biological readout stretched well beyond what you’d guess from a naive reading, because the peptide’s job is to trigger a hormonal response, not to persist. When you evaluate a compound, this is why “the effect lasted X” and “the half-life is Y” can both be true and still be different numbers.

When effects fall short of blood levels

The mismatch runs the other way too: plenty of drug in the blood, little effect.

• A threshold concentration is required. Some effects only appear above a certain level. Once concentration drops below that threshold (which can happen well before the drug is “cleared”), the effect stops even though meaningful drug remains. The action ends earlier than the half-life curve alone implies.
• Tolerance and receptor desensitization. Repeated exposure can blunt the response, so the same blood level produces a smaller effect over time. The drug is present and unchanged; the system has adapted. We cover this for peptides in peptide tolerance and desensitization.
• Hysteresis. In formal PK/PD modeling, the effect often lags behind or leads the plasma concentration, tracing a hysteresis loop rather than a straight line, a mathematical fingerprint that concentration and effect are not the same variable. It reflects delays in the drug reaching its site of action, or in the downstream response building and fading.

A quick contrast table

Question	Half-life	Duration of action
What it measures	Speed of blood clearance	How long the effect lasts
Discipline	Pharmacokinetics	Pharmacodynamics
Set by	Metabolism, excretion, protein binding	Receptor binding, signaling, tolerance, thresholds
Tool that models it	Half-Life Visualizer	Not a clearance curve; needs effect data

Why this matters when you read about a peptide

Marketing and forum posts routinely blur these two. A long half-life gets sold as “works for a week”; a short half-life gets dismissed as “wears off fast.” Both can be wrong. The GLP-1 hormone story makes the point at both ends: native GLP-1 has a two-minute half-life yet its downstream effects on insulin and appetite outlast that tiny window. The research literature notes explicitly that its short plasma half-life “does not reflect its long-lasting beneficial effects.” Meanwhile the engineered weekly agents, covered in how long semaglutide and tirzepatide stay in your system, are dosed on their half-life but their appetite effects follow their own pharmacodynamic timeline.

The practical rule: use half-life for clearance and washout questions (it does heavily inform dosing frequency, as covered in why peptide dosing frequency varies), but do not read it as a duration-of-effect guarantee. When someone claims a compound “keeps working for X,” ask whether that number came from measuring an effect or just from a clearance curve. They are not interchangeable.

The takeaway

Half-life and duration of action answer different questions. Half-life is how fast the drug leaves your blood; duration of action is how long it keeps doing something. Effects outlast blood levels when binding is tight, signaling is slow, or metabolites stay active, and they fall short of blood levels when a threshold is needed or tolerance sets in. “Cleared from the blood” and “no longer working” are two separate events that only sometimes coincide.

Model the clearance side in the Peptide Half-Life Visualizer, and pair it with the Dose Interval Visualizer to reason about repeated dosing, but treat effect duration as its own question backed by its own data.

This article is educational information about pharmacology, not medical advice. Many research peptides are not approved for human use; consult a qualified clinician before making any decision about a compound.

Sources

• Sustained pain relief with dihydroergotamine due to persistent receptor binding — PMC
• Understanding the Hysteresis Loop in PK/PD Relationships — PMC
• The short half-life of GLP-1 does not reflect its long-lasting beneficial effects (context) — PMC
• Elimination Half-Life of Drugs — StatPearls, NCBI Bookshelf